PMV Pharmaceuticals Says Interim Phase 2 PYNNACLE Data Show 46% Overall Response Rate In 76 Evaluable TP53 Y220C Ovarian Cancer Patients, Median Duration Of Response 10.0 Months; Plans NDA Submission In Q1 2027

Benzinga Newsdesk www.benzinga.com Positive 50.4%

Neg 0% Neu 0% Pos 50.4%

Comments

No comments yet. Be the first!